Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 4/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 3/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.30 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13807053 | 0.89 | ALOX5 (0.36) | ALOX5AKT1AKT2 | |
| SCHEMBL10246842 | 0.89 | ALOX5 (0.36) | ALOX5AKT1AKT2 | |
| SCHEMBL10246610 | 0.86 | ALOX5 (0.47) | ALOX5AKT1CD274AKT2 | |
| SCHEMBL10248385 | 0.83 | ALOX5 (0.49) | ALOX5CD274 | |
| SCHEMBL10245519 | 0.82 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL10247144 | 0.80 | ALOX5 (0.47) | ALOX5AKT1CD274AKT2JAK3 | |
| SCHEMBL10245508 | 0.78 | ALOX5 (0.47) | ALOX5AKT1CD274AKT2 | |
| SCHEMBL10248086 | 0.74 | ALOX5 (0.36) | ALOX5AKT1AKT2 | |
| SCHEMBL332120 | 0.73 | ALOX5 (0.61) | ALOX5AKT1CD274AKT2JAK3 | |
| SCHEMBL332552 | 0.73 | ALOX5 (0.55) | ALOX5AKT1CD274JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | ALOX5 1/4885AKT1 3057/4885CD274 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.